28400402|t|Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies
28400402|a|Tumourigenesis is a relatively common event in endocrine tissues. Currently, specific guidelines have been developed for common malignant endocrine tumours which also incorporate advances in molecular targeted therapies (MTT), as in thyroid cancer and gastrointestinal neuroendocrine malignancies. However, there is little information regarding the role and efficacy of MTT in the relatively rare malignant endocrine tumours mainly involving the adrenal medulla, adrenal cortex, pituitary and parathyroid glands. Due to the rarity of these tumours and the lack of prospective studies, current guidelines are mostly based on retrospective data derived from surgical, loco-regional and ablative therapies, and studies with systemic chemotherapy. In addition, in many of these malignancies the prognosis remains poor with individual patients responding differently to currently available treatments, necessitating the development of new personalised therapeutic strategies. Recently, major advances in the molecular understanding of endocrine tumours - based on genomic, epigenomic, and transcriptome analysis - have emerged, resulting in new insights into their pathogenesis and molecular pathology. This in turn has led to the use of novel MTTs in increasing numbers of patients. In this review we aim to present currently existing and evolving data using MTT in the treatment of adrenal, pituitary and malignant parathyroid tumours, and explore the current utility and effectiveness of such therapies and their future evolution.
28400402	0	28	Molecular targeted therapies	T061	C2699893
28400402	32	39	adrenal	T191	C0750887
28400402	41	50	pituitary	T191	C0496842
28400402	55	79	parathyroid malignancies	T191	C0153653
28400402	80	94	Tumourigenesis	T191	C0007621
28400402	118	123	event	T051	C0441471
28400402	127	144	endocrine tissues	T024	C0229524
28400402	166	176	guidelines	T061	C0935576
28400402	208	235	malignant endocrine tumours	T191	C0153658
28400402	259	267	advances	T078	C1519201
28400402	271	299	molecular targeted therapies	T061	C2699893
28400402	301	304	MTT	T061	C2699893
28400402	313	327	thyroid cancer	T191	C0007115
28400402	332	376	gastrointestinal neuroendocrine malignancies	T191	C4303497
28400402	403	414	information	T078	C1533716
28400402	429	433	role	T077	C1705810
28400402	438	446	efficacy	T080	C1280519
28400402	450	453	MTT	T061	C2699893
28400402	472	476	rare	T080	C0522498
28400402	477	504	malignant endocrine tumours	T191	C0153658
28400402	526	541	adrenal medulla	T023	C0001629
28400402	543	557	adrenal cortex	T023	C0001613
28400402	559	568	pituitary	T023	C0032005
28400402	573	591	parathyroid glands	T023	C0030518
28400402	620	627	tumours	T191	C0027651
28400402	644	663	prospective studies	T062	C0033522
28400402	673	683	guidelines	T061	C0935576
28400402	704	722	retrospective data	T062	C0035363
28400402	736	744	surgical	T061	C0543467
28400402	746	759	loco-regional	T061	C0087111
28400402	764	782	ablative therapies	T061	C0547070
28400402	788	795	studies	T059	C0947630
28400402	801	822	systemic chemotherapy	T061	C1883256
28400402	854	866	malignancies	T191	C0006826
28400402	871	880	prognosis	T033	C0278252
28400402	889	893	poor	T080	C0542537
28400402	899	909	individual	T098	C0027361
28400402	910	918	patients	T101	C0030705
28400402	919	929	responding	T201	C0521982
28400402	965	975	treatments	T061	C0087111
28400402	995	1006	development	T169	C1527148
28400402	1027	1049	therapeutic strategies	T061	C0087111
28400402	1067	1075	advances	T078	C1519201
28400402	1083	1092	molecular	T080	C1521991
28400402	1093	1106	understanding	T041	C0233820
28400402	1110	1127	endocrine tumours	T191	C0014132
28400402	1139	1146	genomic	T063	C0796358
28400402	1148	1158	epigenomic	T062	C0242481
28400402	1164	1186	transcriptome analysis	T059,T063	C0752248
28400402	1194	1201	emerged	T080	C1516832
28400402	1220	1228	insights	T041	C0233820
28400402	1240	1252	pathogenesis	T046	C0699748
28400402	1257	1276	molecular pathology	T059	C1979599
28400402	1313	1318	novel	T080	C0205314
28400402	1319	1323	MTTs	T061	C2699893
28400402	1327	1337	increasing	T169	C0442808
28400402	1338	1345	numbers	T081	C0237753
28400402	1349	1357	patients	T101	C0030705
28400402	1367	1373	review	T170	C0282443
28400402	1377	1380	aim	T078	C1947946
28400402	1384	1391	present	T033	C0150312
28400402	1392	1401	currently	T079	C0521116
28400402	1402	1410	existing	T061	C2827950
28400402	1415	1423	evolving	T169	C0332253
28400402	1424	1428	data	T078	C1511726
28400402	1435	1438	MTT	T061	C2699893
28400402	1446	1455	treatment	T061	C0087111
28400402	1459	1466	adrenal	T191	C0001624
28400402	1468	1477	pituitary	T191	C0032019
28400402	1482	1511	malignant parathyroid tumours	T191	C0153653
28400402	1537	1544	utility	T081,T170	C0080277
28400402	1549	1562	effectiveness	T080	C1280519
28400402	1571	1580	therapies	T061	C0087111
28400402	1591	1597	future	T079	C0016884
28400402	1598	1607	evolution	T038	C0282688